IL6 and breast carcinoma: While there are multiple inflammatory pathways and molecules that have been implicated in ER+ breast cancer recurrence5–7, the inflammatory cytokine interleukin-6 (IL-6) and its associated pathway has been shown to be associated with poor outcomes in ER+ breast cancer8.